Market growth Market growth is largely driven by the growing prevalence of targeted therapies, the rising incidence of anaphylaxis, rising preference for self-administration of drugs, usability advantages, the increasing number of regulatory approvals, the availability of generic versions of autoinjectors, favorable reimbursements and government support, and technological advancements. The patent expiry of biologics is also expected to provide growth opportunities for players in the market.

[180 Pages Report] The global autoinjectors market is projected to reach USD 104.9 billion by 2025 from USD 46.0 billion in 2020, at a CAGR of 17.9% from 2020 to 2025.

Market Dynamics

• Growing prevalence of targeted therapies
• Rising incidence of anaphylaxis
• Increasing number of regulatory approvals
• Availability of generic versions of autoinjectors
• Favorable reimbursements and government support
• Ease of use increasing the preference for self-administration

COVID-19 Impact on The Autoinjectors Market

The COVID-19 pandemic has resulted in a global healthcare crisis, causing a shift in healthcare delivery in most regions. Most non-essential procedures and in-hospital therapies were deferred in the first half of 2020 to prevent the spread of the infection and ease the toll on healthcare infrastructure. According to researchers at Indiana University, healthcare visits decreased by around 40% in the first six weeks of the pandemic in the US, from early March to mid-April.

Download PDF Brochure @  https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=173991724  

The current COVID-19 pandemic has resulted in the implementation of a fresh set of protocols that aim to reduce patient visits to hospitals and clinics in non-emergency conditions to prevent both the transmission of the virus as much as make sure healthcare institutions are not overwhelmed. In this situation, the preference for home-use autoinjectors has risen among patients suffering from chronic illnesses and allergies. This also protects vulnerable high-risk populations from exposure to the virus during hospital visits.

The geographical regions mapped in the report are:

1. North America

2. Europe

3. Asia-Pacific

4. Latin America

5. Middle East and Africa

Geographically, the autoinjectors market is segmented into North America, Europe, the Asia Pacific, Latin America, and Middle East & Africa. Growth in the Asia Pacific market is majorly driven by the large diabetes population and increasing healthcare expenditure which has drawn a number of major autoinjector device manufacturers to this region. These companies are increasing their presence in the Asia Pacific market through several approaches, such as establishing sales offices and partnering with local pharmaceutical companies

Request for sample pages @   https://www.marketsandmarkets.com/requestsampleNew.asp?id=173991724  

Market growth Market growth is largely driven by the growing prevalence of targeted therapies, the rising incidence of anaphylaxis, rising preference for self-administration of drugs, usability advantages, the increasing number of regulatory approvals, the availability of generic versions of autoinjectors, favorable reimbursements and government support, and technological advancements. The patent expiry of biologics is also expected to provide growth opportunities for players in the market.

[180 Pages Report] The global autoinjectors market is projected to reach USD 104.9 billion by 2025 from USD 46.0 billion in 2020, at a CAGR of 17.9% from 2020 to 2025.

Market Dynamics

• Growing prevalence of targeted therapies
• Rising incidence of anaphylaxis
• Increasing number of regulatory approvals
• Availability of generic versions of autoinjectors
• Favorable reimbursements and government support
• Ease of use increasing the preference for self-administration

COVID-19 Impact on The Autoinjectors Market

The COVID-19 pandemic has resulted in a global healthcare crisis, causing a shift in healthcare delivery in most regions. Most non-essential procedures and in-hospital therapies were deferred in the first half of 2020 to prevent the spread of the infection and ease the toll on healthcare infrastructure. According to researchers at Indiana University, healthcare visits decreased by around 40% in the first six weeks of the pandemic in the US, from early March to mid-April.

Download PDF Brochure @  https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=173991724  

The current COVID-19 pandemic has resulted in the implementation of a fresh set of protocols that aim to reduce patient visits to hospitals and clinics in non-emergency conditions to prevent both the transmission of the virus as much as make sure healthcare institutions are not overwhelmed. In this situation, the preference for home-use autoinjectors has risen among patients suffering from chronic illnesses and allergies. This also protects vulnerable high-risk populations from exposure to the virus during hospital visits.

The geographical regions mapped in the report are:

1. North America
2. Europe
3. Asia-Pacific
4. Latin America
5. Middle East and Africa

Geographically, the autoinjectors market is segmented into North America, Europe, the Asia Pacific, Latin America, and Middle East & Africa. Growth in the Asia Pacific market is majorly driven by the large diabetes population and increasing healthcare expenditure which has drawn a number of major autoinjector device manufacturers to this region. These companies are increasing their presence in the Asia Pacific market through several approaches, such as establishing sales offices and partnering with local pharmaceutical companies

Request for sample pages @   https://www.marketsandmarkets.com/requestsampleNew.asp?id=173991724  

Market growth is largely driven by the growing prevalence of targeted therapies, the rising incidence of anaphylaxis, rising preference for self-administration of drugs, usability advantages, the increasing number of regulatory approvals, the availability of generic versions of autoinjectors, favorable reimbursements and government support, and technological advancements. The patent expiry of biologics is also expected to provide growth opportunities for players in the market.

[180 Pages Report] The global autoinjectors market is projected to reach USD 104.9 billion by 2025 from USD 46.0 billion in 2020, at a CAGR of 17.9% from 2020 to 2025.

Market Dynamics

• Growing prevalence of targeted therapies
• Rising incidence of anaphylaxis
• Increasing number of regulatory approvals
• Availability of generic versions of autoinjectors
• Favorable reimbursements and government support
• Ease of use increasing the preference for self-administration

COVID-19 Impact on The Autoinjectors Market

The COVID-19 pandemic has resulted in a global healthcare crisis, causing a shift in healthcare delivery in most regions. Most non-essential procedures and in-hospital therapies were deferred in the first half of 2020 to prevent the spread of the infection and ease the toll on healthcare infrastructure. According to researchers at Indiana University, healthcare visits decreased by around 40% in the first six weeks of the pandemic in the US, from early March to mid-April.  

Download PDF Brochure @  https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=173991724 

The current COVID-19 pandemic has resulted in the implementation of a fresh set of protocols that aim to reduce patient visits to hospitals and clinics in non-emergency conditions to prevent both the transmission of the virus as much as make sure healthcare institutions are not overwhelmed. In this situation, the preference for home-use autoinjectors has risen among patients suffering from chronic illnesses and allergies. This also protects vulnerable high-risk populations from exposure to the virus during hospital visits.

The geographical regions mapped in the report are:1. North America2. Europe3. Asia-Pacific4. Latin America5. Middle East and Africa

Geographically, the autoinjectors market is segmented into North America, Europe, the Asia Pacific, Latin America, and Middle East & Africa. Growth in the Asia Pacific market is majorly driven by the large diabetes population and increasing healthcare expenditure which has drawn a number of major autoinjector device manufacturers to this region. These companies are increasing their presence in the Asia Pacific market through several approaches, such as establishing sales offices and partnering with local pharmaceutical companies

Some key players mentioned in the research report are:

Some of the top market players in the global autoinjectors market include AbbVie Inc. (US), Mylan (US), Eli Lilly and Company (US), Ypsomed (Switzerland), Amgen (US), Becton, Dickinson and Company (US), GlaxoSmithKline plc (UK), Johnson & Johnson (US), Teva Pharmaceutical (Israel), Antares Pharma (US), Merck KGaA (Germany), Meridian Medical Technologies, Inc. (US), Roche Diagnostics (Switzerland), Bespak (UK), Bayer (Germany), SHL Medical (Switzerland), Haselmeier (Switzerland), Owen Mumford (UK), Ravimed (Poland), Medeca Pharma AB (Sweden), Cambridge Consultants Ltd. (UK), Flex (US), SMC Ltd. (US), and Promius Pharma (US).

Request for sample pages  @  https://www.marketsandmarkets.com/requestsampleNew.asp?id=173991724 

Market growth is largely driven by the growing prevalence of targeted therapies, the rising incidence of anaphylaxis, rising preference for self-administration of drugs, usability advantages, the increasing number of regulatory approvals, the availability of generic versions of autoinjectors, favorable reimbursements and government support, and technological advancements. The patent expiry of biologics is also expected to provide growth opportunities for players in the market.

[180 Pages Report] The global autoinjectors market is projected to reach USD 104.9 billion by 2025 from USD 46.0 billion in 2020, at a CAGR of 17.9% from 2020 to 2025.

Market Dynamics

• Growing prevalence of targeted therapies
• Rising incidence of anaphylaxis
• Increasing number of regulatory approvals
• Availability of generic versions of autoinjectors
• Favorable reimbursements and government support
• Ease of use increasing the preference for self-administration

COVID-19 Impact on The Autoinjectors Market

The COVID-19 pandemic has resulted in a global healthcare crisis, causing a shift in healthcare delivery in most regions. Most non-essential procedures and in-hospital therapies were deferred in the first half of 2020 to prevent the spread of the infection and ease the toll on healthcare infrastructure. According to researchers at Indiana University, healthcare visits decreased by around 40% in the first six weeks of the pandemic in the US, from early March to mid-April. After restrictions were eased, there has been an overall decline in patients delaying seeking care and treatment in healthcare settings.

In summary, the COVID-19 pandemic has been accelerating the trend of self-injection, empowering patients to have more involvement and control over their treatment. Newer technologies in the autoinjectors market have encouraged this trend, as they allow better management of injection speed, injection site pain, and treatment anxiety.

Download PDF Brochure @  https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=173991724 

Opportunity: Need to limit patient visits and physical contact

The current COVID-19 pandemic has resulted in the implementation of a fresh set of protocols that aim to reduce patient visits to hospitals and clinics in non-emergency conditions to prevent both the transmission of the virus as much as make sure healthcare institutions are not overwhelmed. In this situation, the preference for home-use autoinjectors has risen among patients suffering from chronic illnesses and allergies. This also protects vulnerable high-risk populations from exposure to the virus during hospital visits.

Autoinjectors are being developed to support increased viscosity and concentrations of drugs to reduce administration frequency, thus increasing adherence to recommended drug protocols. These factors present an opportunity for the growth of the autoinjectors market in the current COVID-19 scenario.

The geographical regions mapped in the report are:

Geographically, the autoinjectors market is segmented into North America, Europe, the Asia Pacific, Latin America, and Middle East & Africa. Growth in the Asia Pacific market is majorly driven by the large diabetes population and increasing healthcare expenditure which has drawn a number of major autoinjector device manufacturers to this region. These companies are increasing their presence in the Asia Pacific market through several approaches, such as establishing sales offices and partnering with local pharmaceutical companies

Request for sample pages @   https://www.marketsandmarkets.com/requestsampleNew.asp?id=173991724 

Autoinjectors are used to self-administer drugs for the treatment of various diseases and conditions, such as rheumatoid arthritis, multiple sclerosis, diabetes, and anaphylaxis. Autoinjectors are easy to use, portable, and improve dosing accuracy, making them one of the most popular methods for the self-administration of drugs.

What the Autoinjectors Market Looks Like?

MarketsandMarkets forecasts Autoinjectors market is projected to reach USD 85.31 billion by 2023 from an estimated USD 28.91 billion in 2018, at a CAGR of 24.2%. North America to witness the highest market growth during the forecast period.

Growth in the global autoinjectors market is mainly driven by factors such as the growing prevalence of targeted therapies, the rising incidence of anaphylaxis, the increasing number of regulatory approvals, the availability of generic versions of autoinjectors, favorable reimbursements and government support, and technological advancements in autoinjector devices. The patent expiry of biologics in the coming years is also expected to provide growth opportunities for players in the autoinjectors market.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=173991724

What Drives the Autoinjectors Market?

The growth of the global market for Autoinjectors Market is primarily influenced by the following factors:

• Growing Prevalence of Targeted Therapies
• Rising Incidence of Anaphylaxis
• Increasing Number of Regulatory Approvals
• Availability of Generic Versions of Autoinjectors
• Favorable Reimbursements and Government Support
• Technological Advancements and Design Development
  
  

Disposable autoinjectors are the most-preferred autoinjectors due to their ease of use and the presence of a built-in glass syringe (eliminates the need for manually loading the glass syringe), which makes it more convenient for patients with reduced dexterity or visual impairments.

A majority of autoinjectors are used for self-administration of drugs and are rarely recommended for hospital use to avoid the risk of infection due to use on multiple patients. This is a major factor in driving the market growth. Other factors such as the growing prevalence of chronic diseases and technological advancements are also boosting this market segment.

Recent Developments :

• In 2018, Abbvie and Samsung Bioepis signed a licensing agreement to launch Humira biosimilar in Europe.
• In 2018, Amgen collaborated with Simcere to co-develop and commercialize biosimilars in China.
• In 2018, Haselmeier partnered with Common Sensing to develop self-monitoring injector platforms, which will help patients to record the time and amount of every dose.
• In 2017, Ypsomed opened a new manufacturing facility in Solothurn (Switzerland). This new facility will focus on the production of injection systems.
• In 2017, Johnson & Johnson received FDA approval of SIMPONI for the treatment of adults with active psoriatic arthritis (PsA) or active ankylosing spondylitis (AS).
  
  

Geographical growth scenario of Autoinjectors Market :
The large share of the North American autoinjectors market can primarily be attributed to the rising prevalence of autoimmune and chronic diseases, increasing prevalence of anaphylaxis, and the increasing number of FDA approvals in the region.

Request For Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=173991724